October 17, 2025

SPT Labtech and Agilent Introduce Automated Target Enrichment Protocols for Genomic Workflows

SPT Labtech and Agilent Introduce Automated Target Enrichment Protocols for Genomic Workflows

Cambridge, UK, 08 October 2025: SPT Labtech, a pioneer in the design and development of laboratory automation and liquid handling solutions, and Agilent Technologies Inc. (“Agilent”), a global leader in analytical and clinical laboratory technologies, today announced the introduction of automated target enrichment protocols on SPT Labtech’s firefly®+ platform. Automating genomic workflows, the optimized Target Enrichment protocols support researchers using Agilent’s SureSelect Max DNA Library Prep Kits. 

Available immediately to all firefly+ users on the firefly community cloud, the new protocols enable users to prepare libraries with Agilent’s Library Prep and Target Enrichment panels and have been developed through a collaboration between SPT Labtech’s in-house applications team and Agilent’s R&D and product teams. By leveraging firefly+’s advanced automation, the protocols enable hands-off library prep with increased reproducibility, reduced error rates, and significant time savings.

Development work was carried out on the latest version of Agilent’s Exome V8 and a smaller Comprehensive Cancer Panel (CGP), with applicability across the full range of Agilent’s Target Enrichment panels, providing a streamlined and flexible workflow for laboratories. 

Morten Frost, Chief Commercial Officer at SPT Labtech, said:“Making these protocols available today is a critical step in addressing bottlenecks across sequencing workflows. By combining Agilent’s gold-standard chemistry with firefly+ automation, we are helping labs scale sequencing faster, more reliably, and with greater efficiency.”

Nina Green, Vice President and General Manager of the Clinical Diagnostic Division at Agilent, added: “Agilent’s SureSelect Max DNA Library Prep Kit delivers the robust chemistry and high performance that labs demand for target enrichment. We are pleased to partner with SPT on enabling the first Target Enrichment protocol on the firefly+, enabling researchers to scale their sequencing workflows with greater efficiency.”

Representatives from SPT Labtech (booth #2487) will be attending the American Society of Human Genetics (ASHG) 2025 annual meeting, 14th – 18th October, Boston, MA, where they will be available to discuss this new development.

Media Contact: Dr Ben Rutter, Zyme Communications – ben.rutter@zymecommunications.com

About SPT Labtech

SPT Labtech’s solutions are built to accelerate progress in genomics where demand for high-throughput and cost-effective workflows is ever-increasing. The company specializes in developing compact, user-friendly liquid handling platforms that specifically address the challenges of genomics applications, particularly in next-generation sequencing (NGS). Their flagship firefly platform simplifies complex workflows like NGS library preparation by integrating multiple functions—such as pipetting, dispensing, and incubating—into a single benchtop unit. Through strategic collaborations with key industry partners, SPT Labtech ensures its technologies are validated and optimized for a wide range of genomic chemistries, further cementing its position as a vital player in empowering genomics labs to achieve greater efficiency, reproducibility, and innovation.

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp